 |
|
|
| |
Barriers to Hepatitis C Virus Elimination in Germany:
Why Aren't Diagnosed Patients Initiating Therapy?
|
| |
| |
EASL virtual - European Association for the Study of the Liver's Digital International Liver Congress, 27-29 August 2020
Reported by Jules Levin
Peter Buggisch1, Hans Heiken2, Stefan Mauss3, Bernd Weber4, Maria-Christina Jung5, Herbert Gorne6, Renate Heyne7, Holger Hinrichsen8, Dennis Hidde9, Bettina Konig9, Ana Gabriela Pires dos Santos10, Claus Niederau11, Heiner Wedemeyer12, Thomas Berg131ifi-Institute for Interdisciplinary Medicine, Hamburg, Germany; 2Private Practice, Hanover, Germany; 3Center for HIV and Hepatogastroenterology, Düsseldorf, Germany; 4Praxiszentrum Friedrichsplatz/Competence Center Addiction, Kassel, Germany; 5Liver Centre, Munich, Germany; 6MediZentrum Hamburg, Praxis für Suchtmedizin, Hamburg, Germany; 7Leberzentrum am Checkpoint, Berlin, Germany; 8Centre for Gastroenterology and Hepatology, Kiel, Germany; 9AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany; 10AbbVie Inc., North Chicago, Illinois, United States; 11Katholisches Klinikum Oberhausen, St. Josef-Hospital, Klinik für Innere Medizin, Akademisches Lehrkrankenhaus der Universitat Duisburg-Essen, Oberhausen, Germany; 12Dept of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; 13Clinic and Polyclinic of Gastroenterology, Hepatology, Infectiology, and Pneumology, University Hospital Leipzig, Leipzig, Germany
|
| |
|
|
|
|
|
